Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences, Inc. (NYSE:RCUS) announced that its Compensation Committee granted options for 35,050 shares and restricted stock units for 17,525 shares to 16 new employees. The exercise price is set at $23.62, reflecting the closing stock price on June 8, 2022. These grants were made under the company's 2020 Inducement Plan, approved in January 2020. The company focuses on developing innovative cancer therapies and has accelerated six investigational drugs into clinical trials since its founding in 2015.
Arcus Biosciences (NYSE:RCUS) will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022, at 9:20 a.m. PT. This event will be held at the Terranea Resort in Rancho Palos Verdes, California. A live webcast can be accessed via the Investors & Media section of the Arcus website, with a replay available post-event. Arcus is focused on developing innovative treatments for cancer, having advanced six investigational medicines into clinical studies since its founding in 2015.
Arcus Biosciences, Inc. (NYSE:RCUS) has granted stock options to fifteen new employees, allowing them to purchase 49,650 shares at an exercise price of $19.08, the closing price on May 23, 2022. Additionally, restricted stock units were awarded for 21,725 shares. These equity awards are in line with the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus is dedicated to developing innovative cancer therapies, emphasizing the advancement of first- or best-in-class medicines targeting various cancer-related biology and pathways.
Arcus Biosciences, Inc. (NYSE:RCUS) has granted options to purchase 31,350 shares and restricted stock units for 15,675 shares to twelve new employees. The options have an exercise price of $21.50, based on the closing price from May 9, 2022. This move is part of the company's 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing innovative cancer therapies and has six investigational medicines in clinical studies targeting various cancer-related pathways.
Arcus Biosciences (RCUS) reported promising results from the third interim analysis of its Phase 2 ARC-7 study for domvanalimab in treating metastatic non-small cell lung cancer (NSCLC). The domvanalimab treatment arms showed significant differentiation in overall response rate (ORR) and duration of response (DoR) compared to zimberelimab alone. The company has $1.3 billion in cash, supporting ongoing Phase 3 trials. Expected updates will continue into late 2022, emphasizing their commitment to advancing innovative cancer therapies.
Arcus Biosciences (NYSE:RCUS) announced it will release its financial results and key pipeline updates for Q1 2022 on May 9, 2022, after U.S. markets close. The company focuses on developing innovative cancer treatments and has advanced six investigational medicines into clinical trials. These include combination therapies targeting TIGIT, PD-1, and the adenosine axis, among others. Founded in 2015, Arcus aims to expedite the development of medicines to improve cancer patient outcomes globally.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to thirteen new employees. A total of 29,050 options were granted at an exercise price of $27.31, based on the closing price on April 25, 2022. Additionally, 14,525 restricted stock units were issued. These equity awards are part of the Company’s 2020 Inducement Plan, approved in January 2020, which allows for stock grants under NYSE rules. Arcus focuses on developing innovative cancer therapies through partnerships and clinical studies.
Arcus Biosciences (NYSE:RCUS) has announced the granting of equity awards to 13 new employees. The awards include options to purchase 28,900 shares at an exercise price of $33.70 per share and restricted stock units for a total of 14,450 shares. This action is part of the company's 2020 Inducement Plan, approved in January 2020. Arcus focuses on developing innovative cancer therapies, with six investigational medicines currently in clinical studies targeting key biological pathways.
Arcus Biosciences (NYSE:RCUS) announced the granting of equity awards to eleven new employees, totaling options to purchase 30,950 shares at an exercise price of $32.98, the closing price on March 23, 2022. Additionally, restricted stock units were awarded for 15,475 shares. These grants were made under the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus is focused on developing innovative cancer therapies, including six investigational medicines targeting various pathways.
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of stock options and restricted stock units to 14 new employees. A total of 61,000 stock options at an exercise price of $33.03 per share and 30,500 restricted stock units were granted. These awards are part of the company's 2020 Inducement Plan approved by the Board of Directors in January 2020. Founded in 2015, Arcus focuses on developing innovative therapies for cancer treatment, with an emphasis on combination approaches targeting various biological pathways.